| Rituximab biosimilar (Samsung) | SAIT-101 | Phase 3 Clinical | Samsung Biologics Co Ltd | Anemia; Arthritis, Rheumatoid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Burkitt Lymphoma; Hematologic Neoplasms; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoproliferative Disorders; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Rituximab biosimilar (Boehringer Ingelheim) | BI-695500 | Phase 3 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Anemia; Arthritis, Rheumatoid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Burkitt Lymphoma; Hematologic Neoplasms; Hodgkin Disease; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelomonocytic, Chronic; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoproliferative Disorders; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) | | Phase 3 Clinical | Shanghai Institute of Biological Products Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details |
| Ocrelizumab biosimilar (CinnaGen) | | Phase 3 Clinical | Cinnagen | | Details |
| Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) | B001; B-001; B001A; B001-A; B001C; B001-C | Phase 3 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Lymphoma; Lymphoma, Non-Hodgkin; Multiple Sclerosis; Neuromyelitis Optica | Details |
| Rituximab biosimilar (Nanjing Yoko Biomedical) | GB-241 | Phase 3 Clinical | Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd | Blastic Plasmacytoid Dendritic Cell Neoplasm; Burkitt Lymphoma; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Amulirafusp alfa | IMC-002; IMM-0306 | Phase 3 Clinical | | Glomerulonephritis, Membranous; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nephrosis; Neuromyelitis Optica | Details |
| Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) | | Phase 3 Clinical | Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| Ocrelizumab Biosimilar (BIOCAD) | BCD-281; BCD281 | Phase 3 Clinical | BIOCAD JSC | Multiple Sclerosis, Relapsing-Remitting | Details |
| Ocrelizumab Biosimilar (Sandoz) | CYB-704 | Phase 3 Clinical | Sandoz | | Details |
| Ocrelizumab biosimilar (Amgen) | ABP-692; ABP 692 | Phase 3 Clinical | Amgen Inc | Multiple Sclerosis, Relapsing-Remitting | Details |
| CD19/CD20 bicistronic CAR-T cells therapy (Kite Pharma) | KITE-753 | Phase 3 Clinical | Kite Pharma | Large B Cell Lymphoma; Lymphoma, B-Cell | Details |
| Ocrelizumab biosimilar (Celltrion) | CT-P53 | Phase 3 Clinical | Celltrion Inc | Multiple Sclerosis, Relapsing-Remitting | Details |
| Rondecabtagene autoleucel | IMPT-314; LYL314; LYL-314 | Phase 3 Clinical | ImmPACT Bio USA Inc | Large B Cell Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| Iodine 131 tositumomab | TST/I131-TST | Phase 3 Clinical | Corixa Corp | Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma | Details |
| TQB-2825 | TQB-2825 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell | Details |
| B-007 | B-007; B007 | Phase 3 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Glomerulonephritis, Membranous; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Myasthenia Gravis; Nephrosis; Pemphigus | Details |
| Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) | CART-20; CBM-C20.1; CBM-CD20 1 | Phase 2 Clinical | Pla General Hospital | Hematologic Neoplasms; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) | BAT-4306F | Phase 2 Clinical | Bio-Thera Solutions Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| TRS-005 | TRS-005 | Phase 2 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| BVX20-CD20 antibody (Biocon/Vaccinex) | BVX-20; BVX20-MAb | Phase 2 Clinical | Biocon Ltd, Vaccinex Inc | | Details |
| Rituximab biosimilar (JHL Biotech) | JHL-1101 | Phase 2 Clinical | Eden Biologics Inc | Arthritis, Rheumatoid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Burkitt Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details |
| Zamtocabtagene autoleucel | MB-CART2019.1 | Phase 2 Clinical | Miltenyi Biotec | Central Nervous System Lymphoma; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Richter's Syndrome; Scleroderma, Diffuse; Scleroderma, Systemic | Details |
| Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) | PBCAR-20A | Phase 2 Clinical | Precision Biosciences Inc | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| MDX-2003 | MDX-2003 | Phase 2 Clinical | ModeX Therapeutics Inc | Autoimmune Diseases; Leukemia, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Waldenstrom Macroglobulinemia | Details |
| ELC-301 | ELC301; ELC-301 | Phase 2 Clinical | Elicera Therapeutics AB, Uppsala University | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| JS-203 | JS-203 | Phase 2 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| MBS-303 | MBS-303; MSC-303; MSB-303 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Glomerulonephritis; Lupus Nephritis; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Nephrotic Syndrome | Details |
| UCART-20x22 | UCART-20x22 | Phase 2 Clinical | Cellectis Sa | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| CD19/CD20 bicistronic CAR-T cell therapy (Kite Pharma) | KITE-363 | Phase 2 Clinical | Kite Pharma | Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphoma, B-Cell; Multiple Sclerosis; Myasthenia Gravis; Myositis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Scleroderma, Systemic | Details |
| ACE-1831 | ACE-1831 | Phase 2 Clinical | Acepodia Biotech Inc | Burkitt Lymphoma; Immunoglobulin G4-Related Disease; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Primary mediastinal B cell lymphoma | Details |
| GB-261 | CND261; CND-261; GB-261 | Phase 2 Clinical | Genor Biopharma Co Ltd | Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Scleroderma, Systemic | Details |
| CHO-H01 | CHO-H01 | Phase 2 Clinical | Academia Sinica | Lymphoma, Non-Hodgkin; Neoplasms | Details |
| Allo-QuadCAR01-T | Allo-QuadCAR01-T | Phase 2 Clinical | AvenCell Therapeutics Inc | Leukemia; Lymphoma; Lymphoma, Large B-Cell, Diffuse | Details |
| MB-CART19.1 | | Phase 2 Clinical | Miltenyi Biomedicine Gmbh | Central Nervous System Lymphoma; Dermatomyositis; Leukemia, Lymphoid; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Polymyositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic | Details |
| Chimeric Antigen Receptor T Cells therapy (Institute Of Hematology & Blood Diseases Hospital) | | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | | Details |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Autoimmune Diseases; Hematologic Neoplasms; Neuroblastoma | Details |
| MRG001 | MRG-001 | Phase 2 Clinical | Shanghai Miracogen Inc | Epstein-Barr Virus Infections; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders | Details |
| AZD-5492 | AZD5492 | Phase 2 Clinical | Astrazeneca Plc | Arthritis, Rheumatoid; Leukemia, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Myositis; Neoplasms | Details |
| CD19&CD20 bispecific CAR-T cells therapy(Hebei Taihe Chunyu Biotechnology) | | Phase 2 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells therapy(Institute Of Hematology & Blood Diseases Hospital) | | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | | Details |
| C-CAR168 | C-CAR168 | Phase 2 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Autoimmune Diseases; Encephalitis; Lupus Erythematosus, Systemic; Lupus Nephritis; Multiple Sclerosis; Muscular Diseases; Myasthenia Gravis; Neuromyelitis Optica; Scleroderma, Systemic; Stiff-Person Syndrome | Details |
| SCTB-35 | SCTB35; SCTB-35 | Phase 2 Clinical | SinoCelltech Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoma, B-Cell | Details |
| IPH-6501 | IPH-6501; IPH-65 | Phase 2 Clinical | Innate Pharma SA | Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms | Details |
| CD20 monoclonal antibody（The First Affiliated Hospital of Soochow University） | | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | | Details |
| CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) | | Phase 2 Clinical | Shanghai Cellular Biopharmaceutical Group Ltd | | Details |
| ALETA-001 | ALETA-001 | Phase 2 Clinical | Aleta BioTherapeutics Inc | Hematologic Neoplasms; Leukemia; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
| Rituximab Biosimilar (Istituto Giannina Gaslini) | | Phase 2 Clinical | Istituto Giannina Gaslini | | Details |
| ICP-B02 | CM-355; ICP-B02 | Phase 2 Clinical | Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
| CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | | Phase 2 Clinical | Shenzhen University General Hospital | | Details |
| JMT-601 | JMT-601 | Phase 2 Clinical | Shanghai Jmt-Bio Inc | Glomerulonephritis, Membranous; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Nephrosis | Details |
| Prizloncabtagene autoleucel | JNJ-4496; EXP-039; C-CAR039; C-CAR-039; C CAR 039; EXP0-039; JNJ-90014496 | Phase 2 Clinical | Cellular Biomedicine Group Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| EX-103 | EX-103; EX103 | Phase 2 Clinical | Guangzhou Excelmab Inc | Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | Details |
| Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) | | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Burkitt Lymphoma; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma | Details |
| Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) | | Phase 2 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details |
| MB-106 | MB-106 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Autoimmune Diseases; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia | Details |
| Rituximab biosimilar (International Biotech Center Generium) | GNR-006 | Phase 1 Clinical | International Biotech Center Generium | | Details |
| Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) | LZM-002 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) | | Phase 1 Clinical | Fujian Medical University | Lymphoma, Large B-Cell, Diffuse | Details |
| Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) | | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Burkitt Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
| Rituximab biosimilar (Fred Hutchinson Cancer Research Center) | | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Burkitt Lymphoma; Lymphoma, Large B-Cell, Diffuse; Multicentric Castleman's Disease (MCD); Sarcoma, Kaposi | Details |
| Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) | LUCAR-20S | Phase 1 Clinical | | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell | Details |
| Bendamustine Hydrochloride/Rituximab | | Phase 1 Clinical | 1globe Biomedical Co Ltd | | Details |
| Rituximab biosimilar (Gedeon Richter) | RGB-03 | Phase 1 Clinical | Gedeon Richter | | Details |
| CD20-directed CAR-T cell therapy (Cellular Biomedicine) | C-CAR066 | Phase 1 Clinical | AbelZeta Pharma Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| Yinkang-002 | | Phase 1 Clinical | Yinkang Biopharma Inc. | | Details |
| anti-CD47/CD20 bispecific antibody (Bristol-Myers Squibb Co) | | Phase 1 Clinical | Bristol-Myers Squibb Company | Hematologic Neoplasms; Lymphoma, Non-Hodgkin | Details |
| YT-19/20 | | Phase 1 Clinical | China Immunotech Co Ltd | Leukemia; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| TriCAR T-cells | | Phase 1 Clinical | Children'S Hospital Los Angeles | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| ICG-132 | ICG-132 | Phase 1 Clinical | iCell Gene Therapeutics LLC | | Details |
| Dual Anti-CD19/Anti-CD20 CAR T-Cells (NCI) | | Phase 1 Clinical | National Cancer Institute | Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Primary mediastinal B cell lymphoma | Details |
| CD19/CD20 CAR-T | | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD10 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital) | | Phase 1 Clinical | Southern Medical University Zhujing Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 | Phase 1 Clinical | Poseida Therapeutics Inc | Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Primary mediastinal B cell lymphoma | Details |
| CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) | | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell | Details |
| In vivo CAR-T drug targeting CD20 based on mRNA-LNP therapy (The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army) | | Phase 1 Clinical | The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army | | Details |
| CD19 and CD20 CAR-T Cell Therapy (Senlang Biological Technology) | | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | | Details |
| RN-1701 | RN-1701; RN1701 | Phase 1 Clinical | AlloRunning Therapeutics Co Ltd | | Details |
| JNJ-95566692 | JNJ-95566692 | Phase 1 Clinical | Janssen Research & Development Llc | | Details |
| IMM-0306S | IMM0306S; IMM-0306S | Phase 1 Clinical | | Lupus Erythematosus, Systemic | Details |
| CD19.20.22 CAR T cells therapy (University Of Maryland, Baltimore) | | Phase 1 Clinical | University Of Maryland, Baltimore | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Richter's Syndrome | Details |
| Bispecific Anti-CD19, Anti-CD20 CAR T Cells therapy (University Hospital Basel) | | Phase 1 Clinical | University Hospital Basel | Leukemia, B-Cell; Lymphoma, B-Cell | Details |
| LUCAR-E9D | LUCAR-E9D | Phase 1 Clinical | Beijing GoBroad Hospital | | Details |
| LUCAR-E9K | LUCAR-E9K | Phase 1 Clinical | Beijing GoBroad Hospital | | Details |
| CD20/CD19/CD22 Multi-targeted Chimeric Antigen Receptor T-cell (CAR-T) Therapy (Unicar-Therapy Bio-Medicine Technology) | | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | | Details |
| CT-119X | CT119X | Phase 1 Clinical | Shanghai Tongji Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CT1190-P | CT1190-P | Phase 1 Clinical | Shanghai Tongji Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CT-1192 | CT-1192; KJ-C2219 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic | Details |
| JWCAR-239 | JWCAR239; JWCAR-239 | Phase 1 Clinical | Beijing Cancer Hospital | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell | Details |
| DuoCAR20.19.22-D95 | DuoCAR20.19.22-D95 | Phase 1 Clinical | The University Of Kansas Medical Center | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| HB-2198 | HB2198; HB-2198 | Phase 1 Clinical | Hinge Bio Inc | Lupus Erythematosus, Systemic; Lupus Nephritis; Lupus Vulgaris | Details |
| CT-1190B | CT1190B; CT-1190B | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic | Details |
| AcNK-Sup003 | AcNK-Sup003 | Phase 1 Clinical | SupermAb (BeiJing) Biotech Co Ltd | | Details |
| CD19/CD22-targeting CAR-T Cells therapy(Prekin Biopharmaceutical) | PRG2302; PRG-2302 | Phase 1 Clinical | Shenzhen Pregene Biopharma Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| P-CD19 x CD20 - ALLO1 | RG6540; RG-6540 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, Poseida Therapeutics Inc | | Details |
| JWCAR-201 | JWCAR-201; JWCAR201 | Phase 1 Clinical | Shanghai Ming Ju Biotechnology Co Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse | Details |
| Anti-CD20/CD30-CAR-T Cell therapy(Shanghai Tongji Hospital) | | Phase 1 Clinical | Shanghai Tongji Hospital | Leukemia, B-Cell; Lymphoma; Lymphoma, B-Cell | Details |
| LUCAR-G39D | LUCAR-G39D | Phase 1 Clinical | | | Details |
| Allogenic Chimeric Antigen Receptor(CAR)-T Cell Therapy(Beijing Cancer Hospital) | LUCAR-20SP | Phase 1 Clinical | Beijing Cancer Hospital | | Details |
| Rituximab biosimilar (Mabscale) | | Phase 1 Clinical | Mabscale LLC | | Details |
| JNJ-1493 | JNJ-1493 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Lymphoma, B-Cell | Details |
| GF-CART01 | GF-CART01 | Phase 1 Clinical | GenomeFrontier Therapeutics TW Co Ltd | Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma | Details |
| GCK-01 | GCK-01; GCK01 | Phase 1 Clinical | | | Details |
| Recombinant human anti-CD20 momoclonal antibody(Shanghai Crosslink Pharma) | | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd | Myasthenia Gravis; Pemphigus | Details |
| MB-CART 2219.1 | MB-CART 2219.1 | Phase 1 Clinical | Miltenyi Biotec | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| SAR-448501 | DR-0201; SAR-448501 | Phase 1 Clinical | Dren Bio Inc | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, B-Cell | Details |
| INT-2104 | INT-2104 | Phase 1 Clinical | Interius BioTherapeutics Inc | Hematologic Neoplasms; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells(NIH) | | Phase 1 Clinical | National Cancer Institute | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell | Details |
| RO-7121932 | RO7121932; RO-7121932; RO 7121932; RG-6035 | Phase 1 Clinical | Genentech Inc | | Details |
| TanCART19/20 | | Phase 1 Clinical | Pla General Hospital | | Details |
| LCAR-AIO | LCAR-AIO; VHH CAR-T | Phase 1 Clinical | | Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Myasthenia Gravis; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Neuromyelitis Optica; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| 1-A-46 | 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110; BR-110; GSK-5926371 | Phase 1 Clinical | Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co Ltd | Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms | Details |
| Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) | TRS001 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | | Details |
| Prulacabtagene leucel | ADI-001 | Phase 1 Clinical | Adicet Bio Inc, Regeneron Pharmaceuticals Inc | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Arthritis, Rheumatoid; Autoimmune Diseases; Burkitt Lymphoma; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Myositis; Primary mediastinal B cell lymphoma; Scleroderma, Systemic; Stiff-Person Syndrome | Details |
| CD19/CD20 CAR-T Cell Therapy (PersonGen) | | Phase 1 Clinical | Persongen Biotherapeutics | | Details |
| LY-007 | LY007 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) | | Phase 1 Clinical | First Affiliated Hospital Of Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details |
| Plamotamab | XmAb-13676 | Phase 1 Clinical | Xencor Inc | Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Myositis | Details |
| CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) | | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | | Details |
| Rituximab/Paclitaxel | AR-160 | Phase 1 Clinical | Mayo Clinic | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) | | Clinical | Wuhan BioRaid Biotechnology Co Ltd | | Details |
| 89Zr-Rituximab | | Clinical | Universitair Medisch Centrum Utrecht | Central Nervous System Lymphoma | Details |
| Anti-CD20 chimeric antigen receptor T cell therapy (Yake Biotechnology) | | Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Rituximab biosimilar (Bioxpress) | BXT-2336; BX 2336 | Clinical | Bioxpress Therapeutics Sa | Arthritis, Rheumatoid; Granulomatosis with Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Microscopic Polyangiitis; Pemphigus | Details |
| Rituximab/Bendamustine/Cytarabine | | | Fondazione Italiana Linfomi Onlus | | Details |
